Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

HER2 Genetic Intratumor Heterogeneity Is Associated With Resistance to Trastuzumab and Trastuzumab Emtansine Therapy in Recurrent High-Grade Endometrial Cancer

Modern Pathology(2023)10.1016/j.modpat.2023.100299Source: DataRank Database

HER2 Genetic Intratumor Heterogeneity Is Associated With Resistance to Trastuzumab and Trastuzumab Emtansine Therapy in Recurrent High-Grade Endometrial Cancer is a research paper published in Modern Pathology (2023). On theSindex it has a DataRank of 0. It has been cited 21 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access21 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (4 grants)Topics (24)IDs (PubMed, PMC)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (16)

Weining Ma ORCID,David N. Brown ORCID,Arnaud Da Cruz Paula ORCID,Qin Zhou ORCID,Alexia Iaosonos

Live enrichment

PubMed:37558129 PMC:PMC10841308

NCI NIH HHS

Grant: P30 CA008748

NCATS NIH HHS

Grant: UL1 TR000457

NCATS NIH HHS

Grant: UL1 TR002384

NCI NIH HHS

Grant: P50 CA247749

Fields of Study

FemaleHumansTrastuzumabAdo-Trastuzumab EmtansineIn Situ Hybridization, FluorescenceErb-b2 Receptor Tyrosine KinasesEndometrial NeoplasmsCarcinomaBreast Neoplasms

MeSH Terms

HumansCarcinomaBreast NeoplasmsEndometrial NeoplasmsIn Situ Hybridization, FluorescenceFemaleTrastuzumabAdo-Trastuzumab EmtansineErb-b2 Receptor Tyrosine Kinases

Keywords

Targeted TherapyTrastuzumabHer2Intratumor HeterogeneityUterine Serous CancerHigh-grade Endometrial Cancer